vs
Side-by-side financial comparison of Protagonist Therapeutics, Inc (PTGX) and LiveRamp Holdings, Inc. (RAMP). Click either name above to swap in a different company.
LiveRamp Holdings, Inc. is the larger business by last-quarter revenue ($212.2M vs $170.6M, roughly 1.2× Protagonist Therapeutics, Inc). Protagonist Therapeutics, Inc runs the higher net margin — 77.2% vs 18.8%, a 58.4% gap on every dollar of revenue. On growth, Protagonist Therapeutics, Inc posted the faster year-over-year revenue change (184.4% vs 8.6%).
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel peptide-based targeted therapies for unmet medical needs, primarily covering gastrointestinal disorders, inflammatory diseases and rare disease indications. Its lead product candidates target inflammatory bowel disease and other chronic immune-related conditions, with operations spanning global R&D and partnership collaborations.
LiveRamp Holdings, Inc., is an American SaaS company that offers a data connectivity platform whose services include data onboarding, the transfer of offline data online for marketing purposes.
PTGX vs RAMP — Head-to-Head
Income Statement — Q4 FY2024 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $170.6M | $212.2M |
| Net Profit | $131.7M | $39.9M |
| Gross Margin | — | 71.9% |
| Operating Margin | 74.3% | 18.6% |
| Net Margin | 77.2% | 18.8% |
| Revenue YoY | 184.4% | 8.6% |
| Net Profit YoY | 381.7% | 255.7% |
| EPS (diluted) | $2.01 | $0.62 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $212.2M | ||
| Q3 25 | — | $199.8M | ||
| Q2 25 | — | $194.8M | ||
| Q1 25 | — | $188.7M | ||
| Q4 24 | $170.6M | $195.4M | ||
| Q3 24 | — | $185.5M | ||
| Q2 24 | — | $176.0M | ||
| Q1 24 | $255.0M | $171.9M |
| Q4 25 | — | $39.9M | ||
| Q3 25 | — | $27.4M | ||
| Q2 25 | — | $7.7M | ||
| Q1 25 | — | $-6.3M | ||
| Q4 24 | $131.7M | $11.2M | ||
| Q3 24 | — | $1.7M | ||
| Q2 24 | — | $-7.5M | ||
| Q1 24 | $207.3M | $-5.4M |
| Q4 25 | — | 71.9% | ||
| Q3 25 | — | 70.2% | ||
| Q2 25 | — | 70.1% | ||
| Q1 25 | — | 69.3% | ||
| Q4 24 | — | 71.9% | ||
| Q3 24 | — | 72.4% | ||
| Q2 24 | — | 70.6% | ||
| Q1 24 | — | 72.2% |
| Q4 25 | — | 18.6% | ||
| Q3 25 | — | 10.7% | ||
| Q2 25 | — | 3.7% | ||
| Q1 25 | — | -6.1% | ||
| Q4 24 | 74.3% | 7.5% | ||
| Q3 24 | — | 4.0% | ||
| Q2 24 | — | -3.0% | ||
| Q1 24 | 80.9% | -8.3% |
| Q4 25 | — | 18.8% | ||
| Q3 25 | — | 13.7% | ||
| Q2 25 | — | 4.0% | ||
| Q1 25 | — | -3.3% | ||
| Q4 24 | 77.2% | 5.7% | ||
| Q3 24 | — | 0.9% | ||
| Q2 24 | — | -4.3% | ||
| Q1 24 | 81.3% | -3.1% |
| Q4 25 | — | $0.62 | ||
| Q3 25 | — | $0.42 | ||
| Q2 25 | — | $0.12 | ||
| Q1 25 | — | $-0.10 | ||
| Q4 24 | $2.01 | $0.17 | ||
| Q3 24 | — | $0.03 | ||
| Q2 24 | — | $-0.11 | ||
| Q1 24 | $3.26 | $-0.09 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $418.9M | $403.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $675.3M | $962.3M |
| Total Assets | $744.7M | $1.3B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $403.4M | ||
| Q3 25 | — | $376.9M | ||
| Q2 25 | — | $371.1M | ||
| Q1 25 | — | $420.8M | ||
| Q4 24 | $418.9M | $384.3M | ||
| Q3 24 | — | $348.4M | ||
| Q2 24 | — | $342.7M | ||
| Q1 24 | $322.6M | $368.9M |
| Q4 25 | — | $962.3M | ||
| Q3 25 | — | $943.8M | ||
| Q2 25 | — | $947.8M | ||
| Q1 25 | — | $948.9M | ||
| Q4 24 | $675.3M | $957.7M | ||
| Q3 24 | — | $932.1M | ||
| Q2 24 | — | $951.9M | ||
| Q1 24 | $560.4M | $949.1M |
| Q4 25 | — | $1.3B | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $1.3B | ||
| Q4 24 | $744.7M | $1.3B | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | — | $1.2B | ||
| Q1 24 | $629.3M | $1.2B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $184.2M | — |
| Free Cash FlowOCF − Capex | $182.8M | — |
| FCF MarginFCF / Revenue | 107.1% | — |
| Capex IntensityCapex / Revenue | 0.8% | 0.1% |
| Cash ConversionOCF / Net Profit | 1.40× | — |
| TTM Free Cash FlowTrailing 4 quarters | $101.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | — | $57.4M | ||
| Q2 25 | — | $-15.8M | ||
| Q1 25 | — | — | ||
| Q4 24 | $184.2M | $45.1M | ||
| Q3 24 | — | $55.6M | ||
| Q2 24 | — | $-9.3M | ||
| Q1 24 | $-27.4M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | $56.8M | ||
| Q2 25 | — | $-16.2M | ||
| Q1 25 | — | — | ||
| Q4 24 | $182.8M | $44.8M | ||
| Q3 24 | — | $55.4M | ||
| Q2 24 | — | $-9.6M | ||
| Q1 24 | $-27.7M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 28.4% | ||
| Q2 25 | — | -8.3% | ||
| Q1 25 | — | — | ||
| Q4 24 | 107.1% | 22.9% | ||
| Q3 24 | — | 29.8% | ||
| Q2 24 | — | -5.4% | ||
| Q1 24 | -10.9% | — |
| Q4 25 | — | 0.1% | ||
| Q3 25 | — | 0.3% | ||
| Q2 25 | — | 0.2% | ||
| Q1 25 | — | 0.2% | ||
| Q4 24 | 0.8% | 0.1% | ||
| Q3 24 | — | 0.1% | ||
| Q2 24 | — | 0.1% | ||
| Q1 24 | 0.1% | 1.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | 2.09× | ||
| Q2 25 | — | -2.04× | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.40× | 4.02× | ||
| Q3 24 | — | 32.10× | ||
| Q2 24 | — | — | ||
| Q1 24 | -0.13× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
